PharmTech Drug Digest 11.20
News|Articles|September 1, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
  • Volume 11
  • Issue 9

CordenPharma in France Reports Successful FDA Inspection

The CordenPharma Chenôve, France manufacturing facility completed an FDA Inspection with no 483s reported.

CordenPharma announced on Aug. 31, 2016 that the CordenPharma Chenôve (France) manufacturing facility completed an FDA Inspection and received a successful response with no 483s reported. The previous FDA Inspection took place in 2014.
 
Yves Michon, Managing Director of CordenPharma Chenôve comments, “We are pleased with the outcome of the FDA Inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”

Source: CordenPharma

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.